First Advisor

Robert Strongin

Date of Award

Spring 6-2022

Document Type


Degree Name

Bachelor of Science (B.S.) in Biology and University Honors






fluorescence guided surgery, cancer, fluorophore, affibody, biomedical engineering




Evaluation of the compatibility of a nerve-specific fluorophore and a tumor-specific affibody molecule for use in the field of fluorescence guided surgery (FGS) to improve tumor resection and decreased incidence of iatrogenic nerve damage. A novel near-infrared fluorophore, LGW05-75, and a fluorescently labeled affibody molecule that is in Phase 0 clinical trials, ABY-029, were used to specifically highlight tumor and nerve, respectively. To improve solubility, LGW05-75 was encapsulated in micelles and the pharmacokinetics were studied herein with and without the presence of a tumor to enable selection of the optimal time point for nerve to tumor contrast. A human head and neck cancer cell line, Detroit 562, which has high expression of epidermal growth factor receptors (EGFR) was used for this study to evaluate tumor-specific targeting using ABY-029. The studies are still ongoing, but initial results look promising with both nerve- and tumor-specificity shown.


In Copyright. URI: This Item is protected by copyright and/or related rights. You are free to use this Item in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s).

Persistent Identifier

Available for download on Sunday, May 19, 2024